Repligen Corporation's SEC filings document financial reporting, governance and public-company capital structure for a Nasdaq-listed life sciences company in bioprocessing technology. Recent Form 8-K reports attach earnings releases for quarterly and annual results, financial guidance and non-GAAP measures such as organic revenue, adjusted operating income, adjusted EPS and adjusted EBITDA.
The filing record also includes definitive proxy materials covering board matters, executive compensation and equity awards, along with Form 8-K disclosures on officer appointments, principal accounting officer responsibilities, financial reporting oversight and Sarbanes-Oxley-related infrastructure. Securities registration disclosures identify RGEN common stock, par value $0.01 per share, on the Nasdaq Global Select Market.
REPLIGEN CORP (RGEN) reported that its chief executive officer and director, Loeillot Olivier, exercised employee stock options and sold the resulting shares. On September 21, 2026, he exercised options to acquire 5,426 shares of Common Stock at an exercise price of $141.79 per share, then sold 5,426 shares at $180.00 per share. The filing states that these sales were made under a Rule 10b5-1 trading plan adopted on August 19, 2025.
REPLIGEN CORP (RGEN) has a notice of proposed sale under Rule 144 filed for the account of Olivier Loeillot. The filing covers a planned sale of 5,426 common shares of Repligen on September 21, 2026, to be delivered from a stock option exercise for cash through Fidelity Brokerage Services LLC.
The notice also lists sales by the same person during the prior three months: 5,426 shares of common stock on August 20, 2026 for an aggregate of $976,680.00, and 3,035 shares on September 4, 2026 for an aggregate of $503,506.50.
REPLIGEN CORP (RGEN) reported that long-serving director Karen A. Dawes has notified the company of her intention to retire from the Board of Directors, effective September 30, 2026. Dawes has served on the Board for over twenty years and cited the completion of a successful CEO transition as part of her decision.
The company stated that her retirement is not due to any disagreement with Repligen regarding its operations, policies or procedures. President and Chief Executive Officer Olivier Loeillot signed the report on behalf of Repligen.
REPLIGEN CORP (symbol: RGEN) is the issuer of record for a Form 425 filing submitted to the SEC.
REPLIGEN CORP (symbol: RGEN) is the issuer of record for a Form 8-K filing submitted to the SEC.
REPLIGEN CORP (RGEN) reported that Chief Executive Officer and director Loeillot Olivier disposed of common stock in early September 2026. On September 4, he sold 3,035 shares of common stock at $165.90 per share in an open-market or private transaction, executed under a Rule 10b5-1 trading plan adopted on August 19, 2025. On September 3, 2,842 shares of common stock were withheld by the company to satisfy tax withholding obligations arising from the release of restricted stock units.
Repligen Corporation (RGEN) is registering shares of its common stock to be issued as part of a cash-and-stock acquisition of BioLife Solutions, Inc. Repligen will acquire BioLife through a two-step merger, after which BioLife will become a wholly owned subsidiary and its stock will be delisted from Nasdaq.
For each BioLife share, holders will receive $11.25 in cash plus 0.1442 shares of Repligen common stock, with cash paid instead of fractional Repligen shares. A special virtual meeting of BioLife stockholders on October 5, 2026 will vote on adopting the merger agreement, an advisory compensation proposal, and a meeting adjournment proposal.
BioLife’s board (with one director recused) unanimously recommends voting in favor of all three proposals. Completion of the transaction depends on stockholder approval, antitrust and other regulatory clearances, listing of the new Repligen shares on Nasdaq, and the absence of specified adverse events. BioLife stockholders who meet strict Delaware procedures may seek appraisal instead of the stated merger consideration.
REPLIGEN CORP (RGEN) has a notice of proposed sale of common stock filed under Rule 144 for the account of Olivier Loeillot. The notice covers 3,035 shares of common stock, related to restricted stock vesting on September 3, 2026, to be sold through Fidelity Brokerage Services LLC.
In the prior three months, Loeillot reported a separate sale of 5,426 shares of common stock for an aggregate consideration of $976,680.00.
Repligen Corporation (RGEN) has filed an amended Form S-4 to register shares of its common stock to be issued to stockholders of BioLife Solutions in connection with a two-step merger that will make BioLife a wholly owned subsidiary of Repligen.
Each BioLife share will be converted into the right to receive $11.25 in cash plus 0.1442 shares of Repligen common stock, with cash paid instead of fractional Repligen shares. The exchange ratio is fixed, so the share portion’s value will fluctuate with Repligen’s stock price. A special virtual BioLife stockholder meeting is scheduled for October 5, 2026, with a record date of September 3, 2026, to vote on the merger and related proposals.
Closing is subject to BioLife stockholder approval, antitrust and other regulatory clearances, Nasdaq listing of the new Repligen shares, accuracy of representations and covenants, and absence of specified material adverse effects. BioLife stockholders have appraisal rights under Delaware law if they follow strict procedures instead of taking the merger consideration.